The over-activation of SHP-2 due to a mutation in the PTPN11 gene has been shown to be associated with some hematological malignancies such as B-cell precursor (BCP) ALL as a somatic aberration in 7% of cases [31]. This evidence concerns the gene PTPN11 and acute lymphoblastic leukemia.